P38MAPK inhibitor and uses thereof

Abstract

The present invention demonstrates that p38 MAPK inhibitor induces low density lipoprotein receptor expression 6-8 fold, and further provides the application of such inhibitor in the treatment of hypercholesterolemia.

What is claimed is:  
     
         1 . A compound for inducing low density lipoprotein receptor expression, wherein said compound is selected from the group consisting of a p38 MAPK  inhibitor and a compound that activates p42/44 MAPK .  
     
     
         2 . The compound of  claim 1 , wherein said compound is selected from the group consisting of SB202190 and SB203580.  
     
     
         3 . A method of inducing low density lipoprotein receptor expression in a cell, comprising the step of: 
 administering the compound of  claim 1  to said cell.    
     
     
         4 . The method of  claim 3 , wherein said cell is selected from the group consisting of a hepatic cell and a nonhepatic cell.  
     
     
         5 . The method of  claim 3 , wherein said compound induces said low density lipoprotein receptor expression from about 6-fold to about 8-fold.  
     
     
         6 . The method of  claim 3 , wherein said method further reduces cholesterol level in said cell.  
     
     
         7 . A method of treating an individual having hypercholesterolemia, comprising the step of: 
 administering the compound of  claim 1  to said individual.    
     
     
         8 . The method of  claim 7 , wherein said compound is administered at a concentration range of from about 1 μM to about 100 μM.